Hematopoiesis News Volume 12.46 | Nov 23 2021

    By
    Justin.choi
    -
    0
    149







    2021-11-23 | HN 12.46


    Hematopoiesis News by STEMCELL Technologies
    Vol. 12.46 – 23 November, 2021
    TOP STORY

    Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation

    Scientists reported that the risk of donor cell leukemia in allogeneic hematopoietic cell transplantation was driven by somatic myelodysplastic syndrome–associated mutations or germline predisposition in donors.
    [Journal of Clinical Oncology]

    Full ArticlePress Release
    As a scientist, how you separate the facts from the claims is just as important as how you separate your cells. See for yourself.
    PUBLICATIONSRanked by the impact factor of the journal

    Discrete Regulatory Modules Instruct Hematopoietic Lineage Commitment and Differentiation

    Investigators performed dense, daily, temporal profiling of chromatin accessibility and gene expression changes along ex vivo human erythropoiesis to comprehensively define developmentally regulated DNase I hypersensitive sites and transcripts.
    [Nature Communications]

    Full Article

    Differentiation of Fetal Hematopoietic Stem Cells Requires ARID4B to Restrict Autocrine KITLG/KIT-Src Signaling

    The authors showed that AT-rich interaction domain 4B (ARID4B) interfered with KITLG/KIT signaling, consequently allowing HSC differentiation. Conditional Arid4b knockout in mouse hematopoietic cells blocked fetal HSC differentiation, preventing hematopoiesis.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Genetic and Genomic Analysis of Acute Lymphoblastic Leukemia in Older Adults Reveals a Distinct Profile of Abnormalities: Analysis of 210 Patients from the UKALL14 and UKALL60+ Clinical Trials

    Researchers performed cytogenetic, single nucleotide polymorphism array and next generation sequencing analyses on samples from 210 patients aged above 60 years from the UKALL14 and UKALL60+ clinical trials.
    [Haematologica]

    Abstract

    IL-18R-Mediated HSC Quiescence and MLKL-Dependent Cell Death Limit Hematopoiesis during Infection-Induced Shock

    Using Ixodes ovatus Ehrlichia, a tick-borne pathogen that causes severe shock-like illness and bone marrow aplasia, type I and II interferons promoted the loss of hematopoietic stem and progenitor cells via increased cell death and enforced quiescence.
    [Stem Cell Reports]

    Full ArticleGraphical Abstract

    CD62L Expression Level Determines the Cell Fate of Myeloid Progenitors

    Scientists identified CD62L as a marker to reveal the heterogeneity within progenitors. They confirmed that CD62L-negative common myeloid progenitors (CMPs) represented “bona fide” CMPs, and CD62L-high CMPs were mostly restricted to granulocyte-monocyte progenitors potentials in mice and humans.
    [Stem Cell Reports]

    Full Article

    TAS-116 (Pimitespib), an HSP90 Inhibitor, Exhibits Efficacy in Preclinical Models of Adult T Cell Leukemia

    The authors investigated the anti-adult T cell leukemia/lymphoma effects of a novel oral HSP90 inhibitor TAS-116 and the mechanisms involved in ex vivo and in vivo preclinical models.
    [Cancer Science]

    Abstract

    Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia

    Researchers revealed the breadth of SWI/SNF dependency in leukemia and supported targeting SWI/SNF catalytic function as a potential therapeutic strategy in acute myeloid leukemia.
    [Molecular Cancer Research]

    Abstract

    Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

    Scientists generated ex vivo drug response and multi-omics profiling data for a prospective series of 252 samples from 186 acute myeloid leukemia patients. Functional precision medicine tumor board integrated clinical, molecular and functional data for application in clinical treatment decisions.
    [Cancer Discovery]

    AbstractPress Release

    Patient Similarity Network of Newly Diagnosed Multiple Myeloma Identifies Patient Subgroups with Distinct Genetic Features and Clinical Implications

    The authors introduced multiple myeloma-patient similarity network, the first multiomics patient similarity network of myeloma that enabled accurate dissection of the genetic and molecular landscape of the disease and determined 12 distinct subgroups defined by five data types.
    [Science Advances]

    Full ArticlePress Release

    Circulating miR-146a Expression as a Non-Invasive Predictive Biomarker for Acute Lymphoblastic Leukemia

    Investigators evaluated the usefulness of plasma concentration of circulating mir-146a as a non-invasive biomarker for acute lymphoblastic leukemia. Total RNA including miRNA was isolated from 110 plasma samples of patients, healthy controls, and follow up cases and reverse transcribed.
    [Scientific Reports]

    Full Article
    How have LSCs changed our understanding of myeloid malignancies? Webinar by Dr. Christopher Park, NYU
    REVIEWS

    Circular RNAs in Acute Myeloid Leukemia

    Scientists discern the circular RNAs’ evolving role in elucidating acute myeloid leukemia (AML) biology and therapy resistance and attempt to identify its potential in managing AML.
    [Molecular Cancer]

    Full Article

    Toward Platelet Transcriptomics in Cancer Diagnosis, Prognosis and Therapy

    The authors present a few actionable steps for basic, translational and clinical research communities in advancing the utility of the platelet transcriptome as a highly sensitive biomarker in cancer and collectively enable efforts toward clinical translation and patient benefit.
    [British Journal of Cancer]

    Abstract

    Treatment Failure in Acute Myeloid Leukemia: Focus on the Role of Extracellular Vesicles

    Investigators briefly review the challenges of treating acute myeloblastic leukemia with a glance at the extracellular vesicles’ role in this process.
    [Leukemia Research]

    Abstract
    INDUSTRY AND POLICY NEWS

    Apollomics Inc. Doses First Patient in Phase III Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

    Apollomics, Inc. announced that the first patient has been successfully dosed in a Phase III clinical trial of APL-106 for the treatment of adults with relapsed or refractory acute myeloid leukemia in China.
    [Apollomics, Inc.]

    Press Release

    Graphite Bio Enrolls First Patient in Phase I/II Clinical Trial of GPH101 for Sickle Cell Disease

    Graphite Bio, Inc. announced that the first patient has been enrolled in the company’s Phase I/II clinical trial of GPH101, an investigational gene-edited autologous hematopoietic stem cell therapy designed to directly correct the genetic mutation that causes sickle cell disease.
    [Graphite Bio, Inc.]

    Press Release
    FEATURED EVENT

    ASH Annual Meeting 2021

    December 11 – 14, 2021
    Atlanta, Georgia, United States

    > See All Events

    JOB OPPORTUNITIES

    Research Technician – Hematologic Disorders

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Postdoctoral Researcher – Translational Research

    Karolinska Institutet – Flemingsberg, Sweden

    Research Fellow – Hematologic Malignancies

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Postdoctoral Position – Gene Editing

    Icahn School of Medicine at Mount Sinai – New York, New York, United States

    Postdoctoral Fellow – Functional Genomics of Hematopoiesis

    Boston Children’s Hospital – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter